For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has ...

Shaw and Andrew Aguirre, an oncologist and pancreatic cancer researcher, are co-leading the newly launched Center for RAS Therapeutics, coordinating the prosecution of drugs aimed at KRAS ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.